primary sclerosing cholangitis
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring
Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Ipsen’s tumour treatment receives MHRA marketing authorisation
This is the first approval in the UK for previously treated advanced neuroendocrine tumours
Roche to acquire 89bio in a deal worth up to US$3.5bn
With the agreement, Roche will gain a treatment for moderate to severe MASH
Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours
Treatment options following disease progression have previously been limited for many patients
Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours
The number of patients newly diagnosed with NETs is believed to be on the rise
GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn
Steatotic liver disease affects approximately 5% of the global population
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
The drug has already been approved in the US to treat patients with non-cirrhotic MASH